Novogen granted Canadian Patent for Health Supplements

Novogen, a pharmaceutical company, has been granted patent coverage over itsOTC products being sold in Canada.

The patent covers the isoflavone composition of the productsPromensil(TM), Rimostil(TM), andTrinovin(TM).

dditionally the patent covers the use of isoflavone health supplements for the treatment of menopause symptoms. The CEO of Novogen, Mr. Christopher Naughton, said the grant of this patent significantly strengthens Novogen’s position in the Canadian market. “The issue of this Canadian patent will facilitate Novogen discussions with other companies now engaged in, or planning to enter the market in which Promensil, Rimostil and Trinovin compete in Canada,” Mr. Naughton said. This patent (# 2,136,233) covers isoflavones in health supplement tablets and capsules including those sourced from red clover and soy.

Novogen uses red clover as the source of the four types of isoflavones in its products.